What is HC Wainwright’s Forecast for CorMedix Q4 Earnings?

CorMedix Inc (NASDAQ:CRMD) – Investment analysts at HC Wainwright increased their Q4 2025 EPS estimates for shares of CorMedix in a research note issued on Thursday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.94 per share for the quarter, up from their prior forecast of $0.90. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2029 earnings at $2.57 EPS.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.78. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The business had revenue of $2.73 million during the quarter, compared to analyst estimates of $65.63 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. CorMedix’s revenue for the quarter was up 810.2% on a year-over-year basis. CorMedix has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Other equities analysts have also issued reports about the stock. Zacks Research upgraded shares of CorMedix from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 4th. Needham & Company LLC cut their target price on CorMedix from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Wall Street Zen lowered shares of CorMedix from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 11th. JMP Securities restated a “market outperform” rating and set a $22.00 target price on shares of CorMedix in a research report on Tuesday, September 9th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of CorMedix in a report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $18.33.

CorMedix Price Performance

Shares of NASDAQ:CRMD traded up $0.09 during mid-day trading on Friday, reaching $11.30. 484,251 shares of the company traded hands, compared to its average volume of 2,314,260. The company’s 50 day moving average price is $11.41 and its 200-day moving average price is $12.05. The firm has a market cap of $885.48 million, a PE ratio of 15.05 and a beta of 1.80. CorMedix has a 52 week low of $5.60 and a 52 week high of $17.43.

Hedge Funds Weigh In On CorMedix

Large investors have recently made changes to their positions in the company. Teacher Retirement System of Texas bought a new position in shares of CorMedix during the first quarter valued at approximately $98,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in CorMedix in the 2nd quarter worth about $270,000. Hussman Strategic Advisors Inc. purchased a new stake in CorMedix in the 2nd quarter valued at about $776,000. Trexquant Investment LP grew its stake in CorMedix by 588.9% in the 1st quarter. Trexquant Investment LP now owns 135,487 shares of the company’s stock worth $835,000 after acquiring an additional 115,819 shares in the last quarter. Finally, Swiss National Bank bought a new stake in shares of CorMedix during the first quarter valued at approximately $724,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other CorMedix news, insider Kaufman Beth Zelnick sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $13.41, for a total transaction of $670,500.00. Following the sale, the insider directly owned 180,418 shares of the company’s stock, valued at $2,419,405.38. The trade was a 21.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Myron Kaplan acquired 25,000 shares of the stock in a transaction dated Thursday, October 23rd. The stock was bought at an average cost of $11.02 per share, with a total value of $275,500.00. Following the completion of the purchase, the director directly owned 201,034 shares in the company, valued at approximately $2,215,394.68. The trade was a 14.20% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 163,997 shares of company stock valued at $2,163,617 in the last quarter. 3.10% of the stock is currently owned by insiders.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.